| Bioactivity | CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis[1]. |
| Invitro | CPD-002 (0-64 μM，24-48 h) 对 HUVEC 和 MH7A 细胞具有剂量依赖性的细胞毒性[1]。CPD-002 (0-8 μM，24 h) 通过抑制 F-肌动蛋白表达以及对 MH7A 细胞释放的趋化剂的趋化反应，抑制 VEGF 诱导的 HUVEC 细胞迁移和侵袭[1]。CPD-002 (0-8 μM) 通过抑制 TNF-α、IL-1β、IL-6、IL-8、MMP2 和 MMP9 等炎症介质发挥抗炎活性，从而抑制滑膜血管生成[1]。CPD-002 (0-8 μM，9 天) 在离体大鼠主动脉环测定中，抑制 HUVEC 管形成和主动脉环芽形成[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> CPD-002 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | CPD-002 (15-60 mg/kg，腹腔注射，每天一次共 14 天) 在佐剂诱导的关节炎大鼠模型中表现出抗关节炎和抗血管生成活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 2617376-08-4 |
| Formula | C17H16N4O2S |
| Molar Mass | 340.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jiang F, et al., CPD-002, a novel VEGFR2 inhibitor, relieves rheumatoid arthritis by reducing angiogenesis through the suppression of the VEGFR2/PI3K/AKT signaling pathway. Int Immunopharmacol. 2024 Apr 20;131:111850. |